-
Cardiff City lose compensation case over Emiliano Sala death
-
Several French far-right mayors take down EU flags
-
Air Canada CEO to retire after row over English-only condolence message
-
Oil rises on Trump's Iran threats, stocks take cue on talks
-
Syrian leader pledges to work with Germany on migration, recovery
-
AI agent future is coming, OpenClaw creator tells AFP
-
Cardiff lose 122 mn euro compensation case over Emiliano Sala death
-
Tuchel defends Rice and Saka after England withdrawals
-
G7 ministers tackle economic fallout of Mideast war
-
Tottenham close in on De Zerbi as next boss - reports
-
Kenya's former NY marathon champion Korir gets 5-year doping ban
-
Lukaku says 'could never turn back on Napoli' after treatment row
-
Syrian leader visits Germany to talk war, recovery, refugees
-
Renault says developing ground-based military drone
-
Iran hangs two 'political prisoners' from banned opposition: activists
-
Russia expels UK diplomat on spying allegations
-
Premier League fans back call to scrap VAR
-
Italy hoping to scale World Cup 'Everest' ahead of Bosnia play-off showdown
-
Japan's cherry blossom season dazzles locals and tourists
-
EU ups mackerel quotas to match UK despite overfishing concerns
-
Crude rises, stocks drop as Houthi attacks escalate Iran war
-
Australian Rules player banned for wiping blood on face of opponent
-
Sheep culls put pressure on Greek feta cheese production
-
One man, his dog, and ChatGPT: Australia's AI vaccine saga
-
Israel PM restores access after Latin Patriarch blocked from Holy Sepulchre
-
Israel strikes Tehran as Trump says Iran deal may be reached 'soon'
-
Italy chase World Cup spot as Kosovo bid to make debut
-
Myanmar paves way for junta chief to become civilian president
-
'Long live the shah': Iranian diaspora back war at Washington rally
-
Taiwan opposition leader accepts Xi's invitation to visit China
-
French masonic lodge at heart of murky murder trial
-
US military building 'massive complex' beneath White House ballroom project: Trump
-
IPL captain takes pop at Cricket Australia over record-buy Green
-
G7 ministers set to tackle financial fallout of Mideast war
-
Premier League fans feel the pinch from ticket price hikes
-
Australia to halve fuel tax in response to Middle East war
-
Crude surges, stocks dive as Houthi attacks escalate Iran war
-
Air China resumes flights to North Korea after 6-year pause
-
NBA-best Thunder beat Knicks as Boston seal playoff spot
-
Australian fugitive shot dead by police after seven-month manhunt
-
King Kimi, Max misery, Bearman smash: Japan GP talking points
-
Philippines oil refinery secures 2.5 mn barrels of Russian crude
-
Trump says Russia can deliver oil to Cuba
-
All Blacks prop Williams out of Super Rugby season with back infection
-
Life with AI causing human brain 'fry'
-
Dubious AI detectors drive 'pay-to-humanize' scam
-
Test star Carey the hero as South Australia win Sheffield Shield final
-
Defending champ Kim Hyo-joo holds off Korda to win LPGA Ford Championship
-
Implacable Sinner overpowers Lehecka to win Miami Open
-
Australian police shoot dead fugitive wanted for killing officers
US tells pharmas to make Covid boosters targeting BA.4 and BA.5
The US Food and Drug Administration on Thursday told vaccine makers that Covid boosters for this fall and winter should include components targeting the BA.4 and BA.5 sublineages of Omicron.
Earlier this week, a panel of medical experts convened by the agency voted in favor of updating Covid vaccines against Omicron, with most indicating they would favor shots that target the latest iterations rather than its original form, BA.1, fearing the latter would be too out-of-date.
BA.4 and BA.5, which are more transmissible and immune evasive, now comprise more than 52 percent of US Covid cases, according to an official tracker.
"We have advised manufacturers seeking to update their Covid-19 vaccines that they should develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a two component (bivalent) booster vaccine," the FDA said in a statement.
These vaccines would also need to target the original Wuhan strain, in order to increase the breadth of immune response.
Pfizer and Moderna, which produce messenger RNA Covid vaccines, have developed and tested vaccines against BA.1, and representatives of both companies indicated during the experts' meeting they would need around three months to produce BA.4 and BA.5 vaccines at scale.
Pfizer shared early results showing its BA.4/5 vaccine produced a strong antibody response in mice, but it hasn't yet been trialed in humans.
Novavax, which makes a protein subunit vaccine, said it could offer BA.4/5 vaccines by the end of the year.
The FDA said in its new statement that the companies would need to submit human data prior to authorization.
The "primary series" or first shots a person receives would remain against the original strain, the FDA added.
While previous "variants of concern" like Alpha and Delta eventually petered out, Omicron and its sublineages have dominated throughout 2022, to the point it comprises the vast majority of all Covid in the world, FDA official Jerry Weir told the expert meeting this week.
This makes it more likely that the virus's future evolution will also occur along the Omicron branch of the Covid family tree, he added.
Earlier this month, the World Health Organization also recommended the use of Omicron boosters after a primary series against the original strain.
N.Walker--AT